Journal of stroke and cerebrovascular diseases : the official journal of National Stroke Association · 2026
Efficacy of hyperbaric oxygen therapy for post-stroke depression: Association with inflammatory biomarker reduction in a sham-controlled randomized trial.
СтатьяРандомизированное исследованиеНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Gong Shuang, Tang Min, He Jiayue, Wu Xiangping, Shi Meijun, Yang Mei, Shi Lingli, Huang Ling, Li Longhui, Zhou Dongsheng, Zhao Yuanzhi
Аннотация
BACKGROUND: Post-stroke depression (PSD) affects 29-52% of stroke survivors, with inflammation as a key pathophysiological mechanism. Hyperbaric oxygen therapy (HBOT) may modulate inflammation, but clinical evidence is limited.
METHODS: In this randomized, double-blind, sham-controlled trial, 61 PSD patients were allocated to HBOT (n = 29) or Sham-HBOT (n = 32) groups, respectively. The primary outcome was the change in the 17-item Hamilton Depression Rating Scale (HAMD-17) score from baseline to week 4. NIHSS and MBI scores and serum c-reactive protein (CRP), interleukin-6 (IL-6), tumor necrosis factor-α (TNF-α) were evaluated at baseline as well as 2 and 4 weeks after HBOT intervention.
RESULTS: HAMD-17 scores decreased significantly in the HBOT group vs. sham-group at weeks 2 (p = 0.017) and 4 (p < 0.01). Serum CRP, IL-6, and TNF-α levels were significantly reduced in the HBOT group (all p < 0.01). Reductions in HAMD-17 scores correlated positively with declines in IL-6 (r = 0.38, p < 0.05) and TNF-α (r = 0.42, p < 0.05).
CONCLUSION: HBOT could reduce the levels of serum inflammatory cytokines and inhibit depressive symptoms in PSD patients. Large trials are needed to validate long-term efficacy.
TRIAL REGISTRATION: ChiCTR2100053522(https://www.chictr.org.cn/showproj.html?proj=140799).
METHODS: In this randomized, double-blind, sham-controlled trial, 61 PSD patients were allocated to HBOT (n = 29) or Sham-HBOT (n = 32) groups, respectively. The primary outcome was the change in the 17-item Hamilton Depression Rating Scale (HAMD-17) score from baseline to week 4. NIHSS and MBI scores and serum c-reactive protein (CRP), interleukin-6 (IL-6), tumor necrosis factor-α (TNF-α) were evaluated at baseline as well as 2 and 4 weeks after HBOT intervention.
RESULTS: HAMD-17 scores decreased significantly in the HBOT group vs. sham-group at weeks 2 (p = 0.017) and 4 (p < 0.01). Serum CRP, IL-6, and TNF-α levels were significantly reduced in the HBOT group (all p < 0.01). Reductions in HAMD-17 scores correlated positively with declines in IL-6 (r = 0.38, p < 0.05) and TNF-α (r = 0.42, p < 0.05).
CONCLUSION: HBOT could reduce the levels of serum inflammatory cytokines and inhibit depressive symptoms in PSD patients. Large trials are needed to validate long-term efficacy.
TRIAL REGISTRATION: ChiCTR2100053522(https://www.chictr.org.cn/showproj.html?proj=140799).